The BrUOG337 trial was a phase II trial studying olaparib in patients with localized or advanced PCa, with endpoints measuring prostate specific antigen (PSA) response and progression free survival (PFS) [81, 83]. Here, KLK3 is linked to posterior cortical atrophy.